Literature DB >> 30971477

Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis.

Andrew L Zhou1, Suresh K Swaminathan1, Geoffry L Curran1, Joseph F Poduslo1, Val J Lowe1, Ling Li1, Karunya K Kandimalla2.   

Abstract

Recent studies suggest that apolipoprotein A-I (ApoA-I), the major protein constituent of high-density lipoprotein particles, plays a critical role in preserving cerebrovascular integrity and reducing Alzheimer's risk. ApoA-I present in brain is thought to be primarily derived from the peripheral circulation. Although plasma-to-brain delivery of ApoA-I is claimed to be handled by the blood-cerebrospinal fluid barrier (BCSFB), a contribution by the blood-brain barrier (BBB), which serves as a major portal for protein delivery to brain, cannot be ruled out. In this study, we assessed the permeability-surface area product (PS) of radioiodinated ApoA-I (125I-ApoA-I) in various brain regions of wild-type rats after an intravenous bolus injection. The PS value at the cortex, caudate putamen, hippocampus, thalamus, brain stem, and cerebellum was found to be 0.39, 0.28, 0.28, 0.36, 0.69, and 0.76 (ml/g per second × 10-6), respectively. Solutes delivered into brain via the BCSFB are expected to show greater accumulation in the thalamus due to its periventricular location. The modest permeability for 125I-ApoA-I into the thalamus relative to other regions suggests that BCSFB transport accounts for only a portion of total brain uptake and thus BBB transport cannot be ruled out. In addition, we show that Alexa Flour 647-labeled ApoA-I (AF647-ApoA-I) undergoes clathrin-independent and cholesterol-mediated endocytosis in transformed human cerebral microvascular endothelial cells (hCMEC/D3). Further, Z-series confocal images of the hCMEC/D3 monolayers and Western blot detection of intact ApoA-I on the abluminal side demonstrated AF647-ApoA-I transcytosis across the endothelium. These findings implicate the BBB as a significant portal for ApoA-I delivery into brain.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30971477      PMCID: PMC6538888          DOI: 10.1124/jpet.118.254201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

1.  Cerebrovascular permeability coefficients to sodium, potassium, and chloride.

Authors:  Q R Smith; S I Rapoport
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

2.  Measurement of apolipoprotein A-I in rat high density lipoprotein and in rat plasma by radioimmunoassay.

Authors:  G Schonfeld; M S Frick; A P Bailey
Journal:  J Lipid Res       Date:  1976-01       Impact factor: 5.922

Review 3.  The intracellular trafficking pathway of transferrin.

Authors:  Kristine M Mayle; Alexander M Le; Daniel T Kamei
Journal:  Biochim Biophys Acta       Date:  2011-09-22

4.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

Review 5.  HDL and cognition in neurodegenerative disorders.

Authors:  David A Hottman; Dustin Chernick; Shaowu Cheng; Zhe Wang; Ling Li
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

6.  The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71.

Authors:  Khairunnisa' Mohamed Hussain; Kim Lian Janet Leong; Mary Mah-Lee Ng; Justin Jang Hann Chu
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

7.  Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature.

Authors:  Edward K Agyare; Sarah R Leonard; Geoffry L Curran; Caroline C Yu; Val J Lowe; Anant K Paravastu; Joseph F Poduslo; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2013-03-05       Impact factor: 4.939

Review 8.  Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies.

Authors:  Raphael Zidovetzki; Irena Levitan
Journal:  Biochim Biophys Acta       Date:  2007-04-06

9.  Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.

Authors:  Roy O Weller; Stephen D Preston; Malavika Subash; Roxana O Carare
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

10.  Receptor-mediated endocytosis and brain delivery of therapeutic biologics.

Authors:  Guangqing Xiao; Liang-Shang Gan
Journal:  Int J Cell Biol       Date:  2013-06-11
View more
  17 in total

1.  ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease.

Authors:  Cinzia Marchi; Maria Pia Adorni; Paolo Caffarra; Nicoletta Ronda; Marco Spallazzi; Federica Barocco; Daniela Galimberti; Franco Bernini; Francesca Zimetti
Journal:  J Lipid Res       Date:  2019-06-05       Impact factor: 5.922

Review 2.  Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier.

Authors:  Elizabeth M Rhea; William A Banks
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

Review 3.  Endosomal trafficking in metabolic homeostasis and diseases.

Authors:  Jerome Gilleron; Anja Zeigerer
Journal:  Nat Rev Endocrinol       Date:  2022-10-10       Impact factor: 47.564

4.  Association of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Authors:  Jun-Hui Tong; Shi-Qiang Gong; Yan-Song Zhang; Jian-Ru Dong; Xin Zhong; Min-Jie Wei; Ming-Yan Liu
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

5.  High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-β Distribution between Brain and Plasma.

Authors:  Suresh K Swaminathan; Andrew L Zhou; Kristen M Ahlschwede; Geoffry L Curran; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2020-08-10       Impact factor: 4.030

Review 6.  APOA1: a Protein with Multiple Therapeutic Functions.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Curr Atheroscler Rep       Date:  2021-02-16       Impact factor: 5.113

7.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

8.  The SR-B1 Receptor as a Potential Target for Treating Glioblastoma.

Authors:  Ethan Berney; Nirupama Sabnis; Marlyn Panchoo; Sangram Raut; Rob Dickerman; Andras G Lacko
Journal:  J Oncol       Date:  2019-06-03       Impact factor: 4.375

Review 9.  Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer's Disease: Systematic Review and Meta-Analysis.

Authors:  Marco Zuin; Carlo Cervellati; Alessandro Trentini; Angelina Passaro; Valentina Rosta; Francesca Zimetti; Giovanni Zuliani
Journal:  Diagnostics (Basel)       Date:  2021-05-28

10.  Apolipoprotein A-I in mouse cerebrospinal fluid derives from the liver and intestine via plasma high-density lipoproteins assembled by ABCA1 and LCAT.

Authors:  Maki Tsujita; Boris Vaisman; Liu Chengyu; Kasey C Vickers; Kei-Ichiro Okuhira; Sten Braesch-Andersen; Alan T Remaley
Journal:  FEBS Lett       Date:  2020-10-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.